DDI Pharmaceuticals Inc. announced Tuesday it willreintroduce Palosein, an anti-inflammatory superoxidedismutase (SOD) used by veterinarians for the treatment ofchronic soft tissue inflammation in horses and inflammationassociated with some musculoskeletal conditions in dogs.

The company (NASDAQ:DDIX) plans to begin selling Palosein inthe U.S. in the fourth quarter of 1993.

DDI ceased marketing Palosein several years ago when aprevious agreement with its sole U.S. distributor expired. Thereintroduction is the first major product decision since newmanagement assumed control of the Mountain View, Calif.,company May 10. President Ray Rogers said the company plansan aggressive marketing campaign targeted to veterinarians.

(c) 1997 American Health Consultants. All rights reserved.